Cardiff Oncology
CRDF
52 hedge funds and large institutions have $8.81M invested in Cardiff Oncology in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 5 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
2.37% less ownership
Funds ownership: 15.78% → 13.41% (-2.4%)
5% less funds holding
Funds holding: 55 → 52 (-3)
24% less capital invested
Capital invested by funds: $11.6M → $8.81M (-$2.83M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
74% less call options, than puts
Call options by funds: $34K | Put options by funds: $129K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$128K |
| 2 |
Two Sigma Investments
New York
|
+$102K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$89.6K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$53.6K |
| 5 |
Two Sigma Advisers
New York
|
+$47.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$1.07M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$407K |
| 3 |
Morgan Stanley
New York
|
-$303K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$158K |
| 5 |
Millennium Management
New York
|
-$89K |
CRDF Hedge Fund Activity: Q2 2023 in Review
52 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2023, worth a combined $8.81M — down 24% from $11.6M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CRDF and 2 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 12 added.
The largest buyer was Citadel Advisors, adding an estimated $128K. The largest seller was Citigroup, exiting entirely with an estimated $1.07M sold.
- 52 institutional investors held Cardiff Oncology (CRDF) as of Q2 2023, down from 55 in Q1 2023.
- Funds reported $8.81M of Cardiff Oncology stock for Q2 2023, down 24% quarter-over-quarter.
- 2 funds opened new Cardiff Oncology positions in Q2 2023 and 5 closed out, a net change of -3 holders.
- The largest Cardiff Oncology buyer in Q2 2023 was Citadel Advisors, an estimated $128K added.
- The largest Cardiff Oncology seller in Q2 2023 was Citigroup, an estimated $1.07M sold.
Based on aggregated 13F filings for Q2 2023.